Drugs / TCD601
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06453668 | Apr 2024 → Jul 2026 | amyotrophic lateral sclerosis | ITB-Med LLC | Terminated | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT05669001 | Dec 2023 → Apr 2026 | — | ITB-Med LLC | Completed | No outcome recorded |
| Phase 2 | NCT06025110 | Jan 2023 → Jul 2025 | type 1 diabetes mellitus | ITB-Med LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04803006 | Jan 2023 → Oct 2025 | — | ITB-Med LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04803058 | Dec 2022 → Feb 2026 | — | ITB-Med LLC | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT06019507 | Jun 2022 → Jun 2026 overdue | — | ITB-Med LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06365437 | Jun 2021 → Dec 2024 | — | ITB-Med LLC | Terminated | No outcome recorded |
| Phase 2 | NCT04311632 | May 2021 → Oct 2023 | — | ITB-Med LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TCD601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04803058 ↗ |
| Known as | siplizumab | “A Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and Non-Myeloablative Conditioning, Including...” NCT04803058 ↗4“An Adaptive, Regimen Finding, Safety and Tolerability Study of TCD601 (Siplizumab), a Human Anti-CD2 Antibody, Combined With Donor Bone Marrow Cell Infusion and...” NCT04803006 ↗ “of an Anti-CD2 Monoclonal Antibody, TCD601(Siplizumab) Compared to Anti-thymocyte Globulin” NCT04311632 ↗ “A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients” NCT06025110 ↗ “TCD601 (siplizumab)” NCT06453668 ↗ |
| Modality | Monoclonal antibody | “a Human Anti-CD2 Antibody” NCT04803006 ↗ |
| Target | CD2 | “Human Anti-CD2 Antibody” NCT04803006 ↗ |